Phio Pharmaceuticals is a clinical stage biotechnology company co-founded by the scientist who was awarded the Nobel prize in 2006 for his discovery of RNAi. RNAi is precision targeted immuno-oncology therapy which has broad applications, across multiple cell types. Phio’s proprietary siRNA platform INTASYL®, derived from RNAi is the only self-delivering siRNA focused on immuno-oncology therapeutics.